Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypotrichosis in which the cause of the disease is a mutation in the RPL21 gene.
Features include always present findings: Dry hair and Sparse scalp hair; and very common findings: Sparse or absent eyelashes, Sparse pubic hair, and Sparse axillary hair. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 2 | Abnormal nail morphology, Abnormality of the skin |
RPL21 function has not been fully characterized.
Hypotrichosis 12 is associated with mutations in the RPL21 gene on chromosome 13.
Genetic testing for RPL21 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypotrichosis 12 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 3 very common features, 1 common feature.
No clinical trials have been registered for hypotrichosis 12.
201 publications have been identified in PubMed for hypotrichosis 12. Kisho has analyzed 139 by research type. Research spans Clinical Trial Publication (30%), Review / Meta-Analysis (27%), and Epidemiology / Natural History (24%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 42 | 30% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 10:19 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Research summaries
37 |
27% |
Disease patterns and progression | 34 | 24% |
Laboratory research | 16 | 12% |
Testing and diagnosis research | 3 | 2% |
Patient case studies | 3 | 2% |
New treatment approaches | 3 | 2% |
Other research | 1 | 1% |
Sharma D (2026). [PMID: 41741964](https://pubmed.ncbi.nlm.nih.gov/41741964/). *J Dermatolog Treat*. [Epidemiology / Natural History]
Piraccini BM (2026). [PMID: 40985491](https://pubmed.ncbi.nlm.nih.gov/40985491/). *J Eur Acad Dermatol Venereol*. [Epidemiology / Natural History]
Martin A (2026). [PMID: 41101628](https://pubmed.ncbi.nlm.nih.gov/41101628/). *J Invest Dermatol*. [Clinical Trial Publication]
Zhou C (2026). [PMID: 40090937](https://pubmed.ncbi.nlm.nih.gov/40090937/). *Chin Med J (Engl)*. [Clinical Trial Publication]
Huang J (2026). [PMID: 41216802](https://pubmed.ncbi.nlm.nih.gov/41216802/). *J Cutan Med Surg*. [Epidemiology / Natural History]
Mathai M (2026). [PMID: 40859783](https://pubmed.ncbi.nlm.nih.gov/40859783/). *Vet Dermatol*. [Basic Science / Preclinical]
Zhu Y (2026). [PMID: 40865676](https://pubmed.ncbi.nlm.nih.gov/40865676/). *J Invest Dermatol*. [Basic Science / Preclinical]
Kang D (2026). [PMID: 41490113](https://pubmed.ncbi.nlm.nih.gov/41490113/). *JAMA Netw Open*. [Epidemiology / Natural History]
Starace M (2026). [PMID: 41855013](https://pubmed.ncbi.nlm.nih.gov/41855013/). *Am J Clin Dermatol*. [Epidemiology / Natural History]
Asensio A (2026). [PMID: 40930461](https://pubmed.ncbi.nlm.nih.gov/40930461/). *J Invest Dermatol*. [Basic Science / Preclinical]